For women carrying BRCA1 or BRCA2 mutations, the calculus of cancer prevention has long forced a brutal trade-off: remove the ovaries early and slash cancer risk, or preserve hormonal health and accept elevated danger. Emerging research is beginning to dismantle that binary, reframing BRCA-related ovarian cancer as a heterogeneous risk rather than a uniform sentence—and opening the door to more nuanced, individualized surgical strategies.
Published in the International Journal of Gynecological Cancer, this review synthesizes contemporary data showing that lifetime tubo-ovarian cancer risk among BRCA pathogenic variant carriers varies substantially based on which gene is affected, where along that gene the variant sits, family history burden, and a set of modifiable lifestyle variables including parity, breastfeeding history, and cumulative oral contraceptive use. Risk-reducing salpingo-oophorectomy (RRSO) remains the gold-standard intervention, conferring meaningful reductions in both cancer incidence and all-cause mortality. However, RRSO induces surgical menopause, carrying downstream consequences for cardiovascular, skeletal, cognitive, and sexual health—effects that are particularly significant when the procedure occurs before natural menopause. Against this backdrop, a staged approach—risk-reducing salpingectomy performed first, with oophorectomy deferred—has gained traction, grounded in mounting evidence that most high-grade serous carcinomas originate in the fallopian tube's fimbriated end rather than the ovarian surface itself.
This review represents a clinically important consolidation of shifting paradigms rather than a single novel trial result. The fallopian-tube origin hypothesis has been building for over a decade, but integrating it into actionable surgical protocols has lagged. The staged strategy remains under prospective evaluation—the TUBA-WISP II and INSPIRE trials are among the ongoing studies assessing oncologic equivalence—so the evidence base is not yet definitive. The incorporation of modern probabilistic risk models that blend genomic, familial, and reproductive data into personalized estimates is genuinely incremental progress, helping clinicians move beyond gene-binary counseling. For a population of young women facing life-altering decisions, this individualization is meaningful, though long-term outcome data from the staged approach are still maturing.